 |
| REVIEWS AND PERSPECTIVES FOR THE PRACTICING ONCOLOGIST |
 |
| Top Articles For You and Your Practice |
Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications
Recent years have seen exciting progress in our understanding of Langerhans cell histiocytosis (LCH). Here, Dr. Carl Allen and colleagues, who have been in the forefront of LCH research, explain why the disorder is most likely a myeloid neoplastic disorder rather than a reactive or inflammatory disease, as many had thought. They also review the evidence for potential new therapies based on this model. Read more» |
The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the PCWG3
Since 2008, when the Prostate Cancer Clinical Trials Working Group first developed consensus guidelines for clinical trial design and conduct for castrate-resistant prostate cancer (CRPC), significant advances have been made in the diagnosis and treatment of the disease. This review examines the current understanding of the biology, resistance mechanisms, and emerging therapeutic targets in light of the most recent recommendations, presenting a joint perspective from the medical oncology and urologic disciplines. Read more» |
|
| Coming Soon |
 |
Ground-Glass Opacity Lung Nodules in the Era of Lung Cancer CT Screening: Radiology, Pathology, and Clinical Management
Ground-glass opacity (GGO) lung nodules pose both diagnostic and management challenges—and with the advent of CMS-funded lung cancer CT screening, the number of GGO nodules detected and referred for evaluation and management is sure to increase. Dr. Jesper Pedersen and colleagues present the latest advances in the imaging and pathology of GGO nodules, discuss the most recent relevant US and European guidelines, and offer insights from the experience in screening trials.
|
|
|
| Choose your subscription preference below |
|
|
|
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription. |
|
|
|
|
